Izokibep is under clinical development by Acelyrin and currently in Phase II for Posterior Uveitis. According to GlobalData, Phase II drugs for Posterior Uveitis have a 40% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Izokibep’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Izokibep (ABY-035) is under development for the treatment of posterior uveitis, panuveitis, non-infectious uveitis, intermediate uveitis, patients with moderate-to-severe plaque psoriasis, active psoriatic arthritis with inflammatory musculoskeletal disease, hidradenitis suppurativa. It is administered through subcutaneous route. ABY-035 is a IL-17A blocking molecule. It is developed based on affibody technology. Affibody molecules are antibody mimetics with superior characteristics surpassing monoclonal antibodies and antibody fragments. It was also under development for Takayasu arteritis.
It was also under development for the treatment of ankylosing spondylitis(AS).
Acelyrin is a biopharma company. It focuses on identifying and developing therapeutics for immunology and other unmet medical needs. The company seeks to collaborate with partners, pharmaceutical companies, early-stage start-ups and academicians in identifying and developing products. It is also involved in the development of Los Angeles Biotech Hub. Acelyrin is funded by Westlake Village BioPartners. The company operates with an additional office in San Francisco Bay area, the US. Acelyrin is headquartered in Woodland Hills, California, the US.
For a complete picture of Izokibep’s drug-specific PTSR and LoA scores, buy the report here.